Clinical Trial

Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To evaluate the efficacy and safety of Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections in the treatment of lymphocytopenia in patients with malignant hematological tumors
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-02.
Trial Details
NCT Number NCT06584006
Lead Sponsor The First Affiliated Hospital of Xiamen University
Conditions Hematological Malignancy, Lymphocytopenia
Enrollment 50 participants
Start Date 2024-09-01
Primary Completion 2027-11-30 (estimated)
Study Completion 2028-02-29 (estimated)
Updated on ClinicalTrials.gov 2024-09-19